A phase II/III randomised, comparative study evaluating the safety and immunogenicity of Biological E's live, attenuated Measles-Rubella vaccine in 9–12 month old healthy infants

A phase II/III randomised, comparative study evaluating the safety and immunogenicity of Biological E's live, attenuated Measles-Rubella vaccine in 9–12 month old healthy infants

Background: Measles is a major cause of childhood mortality and one-third of the world's Measles deaths occur in India. Rubella causes lifelong birth defects (Congenital Rubella Syndrome). Although neither condition has a cure, the MR vaccination can successfully prevent both diseases. The safe...

Full description

Bibliographic Details
Main Authors: Subhash Thuluva, SubbaReddy Gunneri, Kishore Turaga, Rammohan Reddy Mogulla, Vijay Yerroju, Kalyankumar Peta, Pothakamuri Venkata Suneetha, Ramesh V. Matur
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Contemporary Clinical Trials Communications
Subjects:
Measles
Rubella
Congenital rubella syndrome
Immunogenicity
Sero-protection
Online Access:http://www.sciencedirect.com/science/article/pii/S2451865423001783

Internet

http://www.sciencedirect.com/science/article/pii/S2451865423001783

Similar Items